08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

SpectRx, Respironics deal

SPRX said it received a $1 million payment from RESP, completing the sale of SPRX's BiliChek bilirubin analyzer for a total of $5 million in base payments. SPRX is eligible for an additional $6.25...
08:00 , Nov 4, 2002 |  BC Week In Review  |  Company News

SpectRx deal

SPRX said it plans to divest its BiliChek Non-invasive Bilirubin Analyzer product line. Sales of the product were $534,000 in the third quarter, which was flat versus $533,000 for the same period last year....
07:00 , Jun 18, 2001 |  BC Week In Review  |  Clinical News

BiliChek: Marketed for use before phototherapy

SPRX published in Pediatrics results of its European trial in 210 newborns in which BiliChek accurately measured jaundice using light reflected from the infant's forehead rather than the standard heel stick blood test. The BiliChek...
08:00 , Mar 26, 2001 |  BC Week In Review  |  Clinical News

BiliChek regulatory update

The FDA granted marketing clearance for BiliChek, a non-invasive biophotonic (optical) bilirubin diagnostic, to monitor infant jaundice during and after treatment. The product previously was approved as a point-of-care screening tool. SpectRx Inc. (SPRX), Norcross,...
07:00 , Aug 14, 2000 |  BC Week In Review  |  Clinical News

BiliChek: Marketed for use before phototherapy

SPRX published in Pediatrics results of its U.S. pivotal trial involving 490 newborn infants of many races in which BiliChek accurately measured jaundice using light reflected from the infant's forehead rather than the standard heel...
08:00 , Mar 22, 1999 |  BC Week In Review  |  Clinical News

SpectRx Inc regulatory update

The FDA granted 510(k) marketing clearance for BiliChek bilirubin analyzer for monitoring infant jaundice. SpectRx Inc. (SPRX), Norcross, Ga.   Business: Diagnostics/Imaging   ...
08:00 , Mar 15, 1999 |  BioCentury  |  Finance

Week 1: So far so good

MorphoSys (NMarkt:MORG) didn't disappoint buyers of its $28 million IPO on the Neuer Markt, gaining 43 percent in trading after last Tuesday's offering to close Friday at Eur35.7, a market cap of Eur122.4 million ($132.6...
07:00 , Oct 5, 1998 |  BC Week In Review  |  Company News

SpectRx, Respironics deal

SPRX said it will receive a $125,000 milestone payment from RESP, its North American marketing partner, for shipping the BiliChek bilirubin analyzer. BiliChek is under FDA review to detect infant jaundice. SpectRx Inc. (SPRX),...
07:00 , Aug 24, 1998 |  BC Week In Review  |  Clinical News

SpectRx regulatory update

SPRX submitted a 510(k) with the FDA for its BiliChek non-invasive bilirubin analyzer to detect infant jaundice. SpectRx Inc. (SPRX), Norcross, Ga.   Business: Diagnostics/Imaging   ...